Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12188/24320
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Infante, Maria Stefania | en_US |
dc.contributor.author | Salmanton-García, Jon | en_US |
dc.contributor.author | Fernández-Cruz, Ana | en_US |
dc.contributor.author | Marchesi, Francesco | en_US |
dc.contributor.author | Jaksic, Ozren | en_US |
dc.contributor.author | Weinbergerová, Barbora | en_US |
dc.contributor.author | Besson, Caroline | en_US |
dc.contributor.author | Duarte, Rafael F | en_US |
dc.contributor.author | Itri, Federico | en_US |
dc.contributor.author | Valković, Toni | en_US |
dc.contributor.author | Szotkovski, Tomáš | en_US |
dc.contributor.author | Busca, Alessandro | en_US |
dc.contributor.author | Guidetti, Anna | en_US |
dc.contributor.author | Glenthøj, Andreas | en_US |
dc.contributor.author | Collins, Graham P | en_US |
dc.contributor.author | Bonuomo, Valentina | en_US |
dc.contributor.author | Sili, Uluhan | en_US |
dc.contributor.author | Seval, Guldane Cengiz | en_US |
dc.contributor.author | Machado, Marina | en_US |
dc.contributor.author | Cordoba, Raul | en_US |
dc.contributor.author | Blennow, Ola | en_US |
dc.contributor.author | Abu-Zeinah, Ghaith | en_US |
dc.contributor.author | Lamure, Sylvain | en_US |
dc.contributor.author | Kulasekararaj, Austin | en_US |
dc.contributor.author | Falces-Romero, Iker | en_US |
dc.contributor.author | Cattaneo, Chiara | en_US |
dc.contributor.author | Van Doesum, Jaap | en_US |
dc.contributor.author | Piukovics, Klára | en_US |
dc.contributor.author | Omrani, Ali S | en_US |
dc.contributor.author | Magliano, Gabriele | en_US |
dc.contributor.author | Ledoux, Marie-Pierre | en_US |
dc.contributor.author | de Ramon, Cristina | en_US |
dc.contributor.author | Cabirta, Alba | en_US |
dc.contributor.author | Verga, Luisa | en_US |
dc.contributor.author | López-García, Alberto | en_US |
dc.contributor.author | Da Silva, Maria Gomes | en_US |
dc.contributor.author | Stojanoski, Zlate | en_US |
dc.contributor.author | Meers, Stef | en_US |
dc.contributor.author | Lahmer, Tobias | en_US |
dc.contributor.author | Martín-Pérez, Sonia | en_US |
dc.contributor.author | Dávila-Vals, Julio | en_US |
dc.contributor.author | Van Praet, Jens | en_US |
dc.contributor.author | Samarkos, Michail | en_US |
dc.contributor.author | Bilgin, Yavuz M | en_US |
dc.contributor.author | Karlsson, Linda Katharina | en_US |
dc.contributor.author | Batinić, Josip | en_US |
dc.contributor.author | Nordlander, Anna | en_US |
dc.contributor.author | Schönlein, Martin | en_US |
dc.contributor.author | Hoenigl, Martin | en_US |
dc.contributor.author | Ráčil, Zdeněk | en_US |
dc.contributor.author | Mladenović, Miloš | en_US |
dc.contributor.author | Hanakova, Michaela | en_US |
dc.contributor.author | Zambrotta, Giovanni Paolo Maria | en_US |
dc.contributor.author | De Jonge, Nick | en_US |
dc.contributor.author | Adžić-Vukičević, Tatjana | en_US |
dc.contributor.author | Nunes-Rodrigues, Raquel | en_US |
dc.contributor.author | Prezioso, Lucia | en_US |
dc.contributor.author | Navrátil, Milan | en_US |
dc.contributor.author | Marchetti, Monia | en_US |
dc.contributor.author | Cuccaro, Annarosa | en_US |
dc.contributor.author | Calbacho, Maria | en_US |
dc.contributor.author | Giordano, Antonio | en_US |
dc.contributor.author | Cornely, Oliver A | en_US |
dc.contributor.author | Hernández-Rivas, José-Ángel | en_US |
dc.contributor.author | Pagano, Livio | en_US |
dc.date.accessioned | 2022-11-11T11:39:04Z | - |
dc.date.available | 2022-11-11T11:39:04Z | - |
dc.date.issued | 2022 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | http://hdl.handle.net/20.500.12188/24320 | - |
dc.description.abstract | Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Frontiers Media SA | en_US |
dc.relation.ispartof | Frontiers in oncology | en_US |
dc.title | B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA) | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.3389/fonc.2022.992137 | - |
dc.identifier.url | https://www.frontiersin.org/articles/10.3389/fonc.2022.992137/full | - |
dc.identifier.volume | 12 | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
crisitem.author.dept | Faculty of Medicine | - |
Appears in Collections: | Faculty of Medicine: Journal Articles |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.